Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVONASDAQ:LPTXNASDAQ:PRLDNASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVOCervoMed$7.22+1.4%$8.64$1.80▼$22.57$62.81M-0.731.34 million shs103,239 shsLPTXLeap Therapeutics$0.40-3.1%$0.38$0.22▼$4.79$16.45M-0.23844,302 shs202,741 shsPRLDPrelude Therapeutics$0.98+1.9%$0.88$0.61▼$6.80$55.22M1.25281,349 shs29,913 shsVTGNVistagen Therapeutics$2.36+6.9%$2.30$1.90▼$4.21$68.17M0.7171,173 shs88,988 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVOCervoMed0.00%-6.56%-18.91%-21.33%-62.55%LPTXLeap Therapeutics0.00%+4.30%+2.22%-3.51%-80.57%PRLDPrelude Therapeutics0.00%-6.79%+8.71%+27.18%-75.38%VTGNVistagen Therapeutics0.00%-6.36%-10.16%-21.63%-37.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRVOCervoMed3.2329 of 5 stars3.45.00.00.02.71.70.6LPTXLeap Therapeutics2.7088 of 5 stars3.14.00.00.03.30.01.3PRLDPrelude Therapeutics3.1084 of 5 stars3.22.00.00.02.75.00.6VTGNVistagen Therapeutics1.0395 of 5 stars0.02.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVOCervoMed 2.89Moderate Buy$27.63282.78% UpsideLPTXLeap Therapeutics 2.25Hold$4.921,138.46% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00309.00% UpsideVTGNVistagen Therapeutics 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest LPTX, VTGN, CRVO, and PRLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.005/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.003/18/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $21.003/17/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVOCervoMed$7.14M8.80N/AN/A$1.30 per share5.55LPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/APRLDPrelude Therapeutics$7M7.89N/AN/A$4.32 per share0.23VTGNVistagen Therapeutics$698K97.67N/AN/A$2.81 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)LPTXLeap Therapeutics-$81.41M-$1.70N/AN/AN/AN/A-116.24%-93.18%8/11/2025 (Estimated)PRLDPrelude Therapeutics-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%8/11/2025 (Estimated)VTGNVistagen Therapeutics-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%8/11/2025 (Estimated)Latest LPTX, VTGN, CRVO, and PRLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/A3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/A3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVOCervoMedN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/AVTGNVistagen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVOCervoMedN/A15.0415.04LPTXLeap TherapeuticsN/A3.973.97PRLDPrelude TherapeuticsN/A7.047.04VTGNVistagen TherapeuticsN/A9.359.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVOCervoMed25.15%LPTXLeap Therapeutics30.46%PRLDPrelude Therapeutics79.72%VTGNVistagen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipCRVOCervoMed35.40%LPTXLeap Therapeutics7.50%PRLDPrelude Therapeutics63.90%VTGNVistagen Therapeutics1.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVOCervoMed48.70 million3.93 millionNot OptionableLPTXLeap Therapeutics4041.44 million36.25 millionOptionablePRLDPrelude Therapeutics12056.46 million20.47 millionOptionableVTGNVistagen Therapeutics4028.86 million28.49 millionOptionableLPTX, VTGN, CRVO, and PRLD HeadlinesRecent News About These CompaniesInsights into VistaGen Therapeutics's Upcoming EarningsJune 16 at 10:43 AM | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16 at 8:51 AM | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen Therapeutics (VTGN) to Release Earnings on TuesdayJune 3, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?May 28, 2025 | marketbeat.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comWhy Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%April 8, 2025 | aaii.comVistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call TranscriptFebruary 15, 2025 | msn.comVistaGen’s Earnings Call: Progress and ChallengesFebruary 14, 2025 | tipranks.comVistagen: Pherine Candidate Proof Of Concept Continues With Fifth IndicationFebruary 14, 2025 | seekingalpha.comStemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc SharesFebruary 14, 2025 | gurufocus.comVistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...February 14, 2025 | gurufocus.comQ3 2025 Vistagen Therapeutics Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comVistagen advances Phase 3 SAD trials with 2025 data readout targetFebruary 13, 2025 | msn.comVistagen reports Q3 EPS (46c) vs (22c) last yearFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net lossFebruary 13, 2025 | msn.comVistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue EstimatesFebruary 13, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, VTGN, CRVO, and PRLD Company DescriptionsCervoMed NASDAQ:CRVO$7.22 +0.10 (+1.36%) Closing price 03:58 PM EasternExtended Trading$7.24 +0.02 (+0.25%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Leap Therapeutics NASDAQ:LPTX$0.40 -0.01 (-3.15%) Closing price 03:59 PM EasternExtended Trading$0.40 0.00 (-0.50%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Prelude Therapeutics NASDAQ:PRLD$0.98 +0.02 (+1.86%) Closing price 03:59 PM EasternExtended Trading$0.97 0.00 (-0.41%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Vistagen Therapeutics NASDAQ:VTGN$2.36 +0.15 (+6.88%) Closing price 03:59 PM EasternExtended Trading$2.36 -0.01 (-0.30%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
